Checkmate 205: the use of nivolumab to treat relapsed Hodgkin lymphoma

Anas Younes, MD of Memorial Sloan Kettering Cancer Center, New York, NY talks about Checkmate 205, a registrational trial of nivolumab for the treatment of relapsed Hodgkin lymphoma, which lead to the approval of this treatment by the Food and Drug Administration (FDA). Checkmate 205 (NCT02181738) was initiated based on a previous Phase I study with 23 patients that showed response rates of 70%, contrasting with other studies that presented lower response rates (20–30%). Based on the promising data from the Phase I trial, two registrational trials were initiated, one with nivolumab, and one with pembrolizumab, seeking potential FDA approval. Checkmate 205, had 80 Hodgkin lymphoma patients enrolled, with a response rate of 66%. This data was presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, in Chicago, IL.

Share this video